Related Experiment Video
Updated: Jun 5, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
[Experimental studies on the antitumor immunity induced by total laryngeal carcinoma RNA- transfected dendritic
Xuefeng Wang1, Li Zhang, Xiaoyuan Du
1Department of Otolaryngology, the First Affiliated Hospital of Liaoning Medical College, Jinzhou, 121001, China. jzswwang@126.com
Objective:
The efficiency of antitumor immunity induced by dendritic cells (DCs) transfected with total RNA of laryngeal carcinoma cells was explored.
Method:
DCs, induced from human peripheral blood mononuclear cells, were transfected with total RNA of laryngeal carcinoma cells. The specific antitumor immunity of cytotoxic T Lymphocytes (CTLs) that were actived by RNA-transfected DCs were detected by MTT methods in vitro. In vivo, antitumor-specific CTLs were subcutaneously injected into the nude mice previously. After 7 days, the laryngeal carcinoma cells were seeded and the tumor occurrence rate was observed. Tumor-loaded nude mice were treated by specific CTLs once (the treated group) or twice (the retreated group). The growth of the implanted tumor was observed too.
Result:
DCs that transfected with tumor RNA can significantly active CTLs which induced antitumor-specific immune response against laryngeal carcinoma in vitro. In vivo, the tumor occurrence rate of the treatment group was predominantly reduced compared with that of the control (P < 0.01). The implanted tumor size of the treated and retreated groups were both significantly reduced (P < 0.05, P < 0.01) compared with the control too, especially the retreated ones (P < 0.05).
Conclusion:
The tumor RNA loaded DCs can significantly active CTLs and the antitumor specific CTLs can both induce antitumor specific immune response against laryngeal carcinoma in vitro and inhibit the growth of the implanted tumor in vivo.
